Table 1 Patient characteristics

No. of enrolled

15

100.0%

Age, y

Median

56

Range

44-66

Chemotherapy

neoadjuvant

3

20.0%

adjuvant

10

66.7%

palliative

2

13.3%

tumor hormone receptor

ER(+), PR(+)

5

33.3%

ER(+), PR(-)

3

20.0%

ER(-), PR(+)

1

6.7%

ER(-), PR(-)

5

33.3%

not applicable

1

6.7%

Her2/neu

Absent

5

33.3%

1+

3

20.0%

2+

4

26.7%

3+

2

13.3%

not applicable

1

6.7%

GCSF administration

Yes

7

46.7%

No

8

53.3%

pT stage*

pT1

3

20.0%

pT2

9

60.0%

pT3

0

0.0%

pT4

3

20.0%

pN stage*

pN0

6

40.0%

pN1

4

26.7%

pN2

3

20.0%

pN3

1

6.7%

not applicable

1

6.7%

Tumor grade

grade 1

2

13.3%

grade 2

6

40.0%

grade 3

6

40.0%

not applicable

1

6.7%

Distant metastases

Yes

2

13.3%

No

13

86.7%

Chemotherapy regimen

Anthracycline-based

7

46.7%

Taxane-based

7

46.7%

Others**

2

13.3%